Skip to content
★ Sign in to follow
CB
Total declarations
10
Company
1
▲ Purchases (10 ops.)
€21k
▼ Sales (0 ops.)
—

Latest filing published 04 Feb 2019 for Opus Genetics, Inc., €5,554.

Filing timeline

BuySale
Charles Beever

Insider track record

Disclosed buys
10
Disclosed sells
0
Signal history

No signal scores available.

Closed purchases

Market purchases
10
Positive at T+90
0%
Median T+90
-54.2%

Based on 10 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

  • Filed 04 Feb 2019 · 2835 days ago · €5,554
    -71.6%
    Entry US$29.28 · Close at T+365 US$8.32
  • Filed 10 Apr 2008 · 6787 days ago · €1,580
    -71.2%
    Entry US$1,152.00 · Close at T+365 US$331.20

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Charles Beever: trading record in brief

Charles Beever is a declared insider of Opus Genetics, Inc., with filings sourced from SEC (Form 4). Between 8 April 2008 and 31 January 2019, the trades on record add up to 10 filings.

Every open-market trade on record is a purchase: 10 purchases worth €21k, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Since January 2019: 1 purchase and no sales on the market.

In size, the median ticket on the buying side is €1,185. After 10 purchases with a full 90-day history, the hit rate stands at 0% and the median 90-day move at -54.2%. These figures describe past trades and do not predict future prices.

Most recently, on 4 February 2019, the filings show an open-market purchase worth €5,554 in Opus Genetics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Companies and markets linked to Charles Beever

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations10 total
  • ▲
    DirectorExecutivesOpus Genetics, Inc.
    6,380 USD37SEC
    10,000 shares@ US$0.638100.0% of flowCommon StockSEC:0001140361-19-002419:0
    Canonical exit: 1 May 2019 (T+90)
  • ▲
    DirectorExecutivesOpus Genetics, Inc.
    2,500 USD0SEC
    1,000 shares@ US$2.50Common StockSEC:0001140361-08-009286:0
    Canonical exit: 7 Jul 2008 (T+90)
  • ▲
    DirectorExecutivesOpus Genetics, Inc.
    8,405 USD0SEC
    3,362 shares@ US$2.50Common StockSEC:0001140361-08-009286:1
    Canonical exit: 7 Jul 2008 (T+90)
  • ▲
    DirectorExecutivesOpus Genetics, Inc.
    1,250 USD0SEC
    500 shares@ US$2.50Common StockSEC:0001140361-08-009286:2
    Canonical exit: 7 Jul 2008 (T+90)
  • ▲
    DirectorExecutivesOpus Genetics, Inc.
    4,900 USD0SEC
    1,960 shares@ US$2.50Common StockSEC:0001140361-08-009286:3
    Canonical exit: 7 Jul 2008 (T+90)
  • ▲
    DirectorExecutivesOpus Genetics, Inc.
    1,245 USD0SEC
    500 shares@ US$2.49Common StockSEC:0001140361-08-009286:4
    Canonical exit: 7 Jul 2008 (T+90)
  • ▲
    DirectorExecutivesOpus Genetics, Inc.
    2,827 USD0SEC
    1,178 shares@ US$2.40Common StockSEC:0001140361-08-009286:5
    Canonical exit: 7 Jul 2008 (T+90)
  • ▲
    DirectorExecutivesOpus Genetics, Inc.
    1,175 USD0SEC
    500 shares@ US$2.35Common StockSEC:0001140361-08-009286:6
    Canonical exit: 7 Jul 2008 (T+90)
  • ▲
    DirectorExecutivesOpus Genetics, Inc.
    1,150 USD0SEC
    500 shares@ US$2.30Common StockSEC:0001140361-08-009286:7
    Canonical exit: 7 Jul 2008 (T+90)
  • ▲
    DirectorExecutivesOpus Genetics, Inc.
    1,125 USD0SEC
    500 shares@ US$2.25Common StockSEC:0001140361-08-009286:8
    Canonical exit: 7 Jul 2008 (T+90)

10 of 10 declarations